MiRNA-based therapy for Human Cancer: MiRNA-185 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target genes, 20/October/2014, 6.17 am

MiRNA-based therapy for Alzhemer’s disease and tauopathies: MiRNA-520c decreases tau phosphorylation and ameliorates tau pathology via down regulation of its target gene, 20/October/2014, 6.13 am
October 20, 2014
Mechanistic & therapeutic insights into tumorigenesis: SNAI2 increases the expression of MiR-17-92 via down regulation of its target gene, 20/October/2014, 6.39 am
October 20, 2014
Show all

The 1989 Nobel prize winner in Chemistry, Prof. Thomas R. Cech from the University of Colorado BioFrontiers Institute, USA has published a research paper in the 13 December 2012 Nature (492(7428):285-9; I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.”  This study provides mechanistic insights into how TPP1 regulates telomerase function.

In connection with this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: MiRNA-based therapy for Human Cancer: MiRNA-185 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target genes.  Remarkably, over 90% human tumors over express telomerase, suggesting that inhibition of its activity may increase the efficacy of anticancer therapy.  Together, this study suggests that pharmacological formulations encompassing “miR-185 or its activators may be used to treat human cancers.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan,   MiRNA-based therapy for Human Cancer: MiRNA-520c suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target genes, 20/October/2014, 6.17 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.